Page 4 - Lawrence Blatt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aligos Therapeutics Shares Hit All-Time Low After Private Placement

By Dean Seal Shares of Aligos Therapeutics hit an all-time low after the company struck a deal to raise about $92 million in a private placement. The stock.

Lawrence blattAligos therapeuticsChief executive lawrence blattDean sealArticle normalBiotechnology servicesHealthcare life sciencesCorporate fundingOwnership changesAcquisitions mergers shareholdingsCorporate actionsCorporate industrial newsPrivate placementsContent typesFactiva filtersC amp ampe industry news filter

Aligos Therapeutics Announces Award of an $8 5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558

03.10.2023 - - NIAID contract will support conducting nonclinical and clinical studies to advance ALG-097558 into future Phase 2/3 studies - This is the second NIH-funding received to advance the development of ALG-097558 - First in human Phase 1 study . Seite 1

Lawrence blattAligos therapeutics incNational institute of allergyNational instituteInfectious diseasesAligos therapeutics chartLigos therapeutics kursLigos therapeutics aktie

Aligos Therapeutics (ALGS) Announces IND Clearance for NASH lead, ALG-055009

Aligos Therapeutics (ALGS) Announces IND Clearance for NASH lead, ALG-055009
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Stephen harrisonMattheww mcclureLawrence blattDrug administrationAligos therapeutics incAligos therapeuticsInvestigational new drugChief executive officerChief medical officerPrincipal investigator

Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

- Phase 2a NASH protocol on track to be submitted to the IND in Q4 2023, enrollment expected to begin in Q1 2024SOUTH SAN FRANCISCO, Calif., Sept. 21, 2023 Aligos Therapeutics, Inc. , a clinical.

Corey davisStephen harrisonVeronica eamesMattheww mcclureLawrence blattAligos therapeutics incExchange commissionLifesci communicationsExchange commission onDrug administrationInvestigational new drugChief executive officerChief medical officerPrincipal investigatorSecurities litigation reform actAligo quarterly report

Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009

Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Veronica eamesMattheww mcclureCorey davisStephen harrisonLawrence blattLifesci communicationsExchange commissionAligos therapeutics incExchange commission onRadcliffe department of medicineUniversity of oxfordPrincipal investigatorChief medical officerVisiting professorRadcliffe departmentSecurities litigation reform act